Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02267629 · ClinicalTrials.gov registry record · Phase 2

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

A Phase 2 study of Obsessive Compulsive Disorder (OCD), sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
7
Enrollment target
1
Study location

NCT02267629 is a Phase 2 study of Obsessive Compulsive Disorder (OCD) that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 7 participants, below the 243-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02267629, a Phase 2 study of Obsessive Compulsive Disorder (OCD), has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.

Conditions Studied

Obsessive Compulsive Disorder (OCD)

Interventions

  • DRUG Rapastinel (formerly GLYX-13)

Study Locations (1)

New York

  • New York State Psychiatric Insitute - New York

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2014-10
Est. Completion 2016-02
Phase Phase 2

Sponsor

New York State Psychiatric Institute

364 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02267629

The ClinicalTrials.gov registry entry for NCT02267629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (97% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obsessive Compulsive Disorder (OCD) appearing as the primary indexed condition, and to 1 intervention - of which Rapastinel (formerly GLYX-13) is the first listed.

NCT02267629 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02267629 about?

NCT02267629 is a clinical study titled "Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder". This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respon...

What is the current status of trial NCT02267629?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2014-10. Estimated completion is 2016-02.

What conditions does trial NCT02267629 study?

This clinical trial studies the following conditions: Obsessive Compulsive Disorder (OCD).

What interventions are being tested in trial NCT02267629?

The interventions under investigation include: Rapastinel (formerly GLYX-13) (DRUG).

Who is sponsoring clinical trial NCT02267629?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02267629 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obsessive Compulsive Disorder (OCD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obsessive Compulsive Disorder (OCD)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.